Gilead Sciences: Remdesivir Remains A Distraction [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
SummaryGilead Sciences remains too focused on Remdesivir as a treatment for COVID-19 despite no expected long-term benefit.The biopharma faces demand hits to key HIV and HCV franchise drugs.A stock shakeout to the mid-$60s would make Gilead Sciences appealing again around 10x normalized EPS estimates.AsGILDQ2 resultsinvestment thesisImage Source: Gilead Sciences websiteCOVID-19 ImpactGilead Sciences fell 4% last Friday following disappointing Q2 earnings. The company finds itself in the odd position of benefitting in the short term from Remdesivir sales while seeing key HIV and HCV franchises disrupted during the pandemic.The biopharma even raised full-year revenue guidance by up to $2.8 billion to no avail. The market is not sold on the Remdesivir boost lasting while knowing the long-term story is getting worse as new patient starts in HCV and HIV patient transitions to Biktarvy have been delayed.Q2 '20 presentationFor this reason, investors likely fear the Q2 weakness is more reflec
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences Announces First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Announces First Quarter 2024 Financial ResultsBusiness Wire
- Built environment thought leaders discuss pathways to circular economy at Tarkett's third annual Circularity Summit [Yahoo! Finance]Yahoo! Finance
- Notable earnings after Thursday's close [Seeking Alpha]Seeking Alpha
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at HSBC Holdings plc from a "reduce" rating to a "hold" rating. They now have a $69.00 price target on the stock.MarketBeat
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- GILD's page on the SEC website